Navigation Links
BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
Date:8/19/2007

WOBURN, Mass., Aug. 15 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that it has appointed Dr. Thaddeus Pullano, 53, as Vice President of Quality Assurance.

(Photo: http://www.newscom.com/cgi-bin/prnh/20070815/NYW022 )

Previously, Dr. Pullano served as the Vice President of Quality Systems for Acambis from 2003 to 2007. In this role, he was responsible for all aspects of Quality Systems, including oversight of vaccine manufacturing and clinical quality assurance. Prior to joining Acambis, Dr. Pullano was responsible for quality assurance at Transkaryotic Therapies as the Company transitioned from R&D to manufacturing operations. He has also held a number of positions in quality assurance at Wyeth Vaccines. Dr. Pullano holds a Ph.D. in Biochemistry from the University of Southern California and a BS in Biochemistry from the State University of New York at Binghamton.

Philip Astley-Sparke, President & CEO of BioVex Inc, said:

"Thad has direct and extensive experience with quality systems supporting the manufacture and release of biologics for clinical trials and commercial sale. He becomes part of the core team dedicated to moving our Woburn manufacturing facility, which will supply Phase III and launch grade material, towards operational status."

About BioVex

BioVex is a privately held biotechnology Company based in Woburn. MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

BioVex's lead cancer program, OncoVEX(GM-CSF), is an oncolytic virus that selectively destroys tumor cells accompanied by the induction of a systemic immune response. OncoVEX(GM-CSF) is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Preliminary data from these studies has been very encouraging demonstrating OncoVEX(GM-CSF) has the potential to treat both local and metastatic disease. The Company is currently preparing for an initial registration study in melanoma where multiple responses have been demonstrated in an ongoing Phase II trial testing OncoVEX(GM-CSF) as stand alone therapy in patients with stage IIIc and stage IV metastatic disease.

The Company's second program is a vaccine for genital herpes, ImmunoVEX(HSV2), which provides complete protection in animal models of the disease. A Phase I study with ImmunoVEX(HSV2) is scheduled to initiate later this year.

For more information visit the company's website at http://www.biovex.com.


'/>"/>
SOURCE BioVex

Copyright©2007 PR Newswire.

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... MA (PRWEB) , ... August 22, 2017 , ... ... new service pipeline built upon patented KBioBox technology, the extended GUIDE-Seq ananlysis. KBioBox ... source GUIDE-Seq computation pipeline to be provide scientists with easy to understand reports, ...
(Date:8/21/2017)... ... August 21, 2017 , ... Baltimore biotech firm, PathSensors, ... to bring its proprietary CANARY pathogen detection technology and high throughput testing solutions ... has purchased an undisclosed number of PathSensors’ Zephyr pathogen detection instruments and will ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... that they will feature Federal Hybrids, Inc. in an upcoming episode, scheduled to ... , American Farmer will explore Federal Hybrids, the independent, family-owned seed company. Educating ...
(Date:8/16/2017)... PA (PRWEB) , ... August 16, 2017 , ... ... taking part in sessions at the ISPE Annual Meeting and Expo , to ... San Diego Marina. The event’s theme is “Driving innovation to advance patient therapies.” , ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 ... Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video ... and Region - Global Forecast to 2022", published by ... in 2016 and is projected to reach USD 75.64 ... 2017 and 2022. The base year considered for the ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology ... object recognition technologies, today announced the release of ... (SDK), which provides improved facial recognition using up ... on a single computer. The new version uses ... improve accuracy, and it utilizes a Graphing Processing ...
Breaking Biology News(10 mins):